


**BRCA1 and BRCA2 mutation testing guidelines<sup>1</sup>****Results****BRCA1/2 mutation identified:** see Protocol 3**BRCA1/2 mutation not identified:** see Protocol 1 for breast screening recommendation**BRCA1/2 variants/VUS identified:** CIGMA report will be issued for internal results\*. For external results email: vus@icr.ac.uk**Notes**<sup>1</sup>The above criteria relate to a full gene screen of *BRCA1* and *BRCA2*, individuals of Ashkenazi Jewish heritage may be eligible for founder mutation testing.\*<sup>2</sup>Currently eligible for testing within Mainstreaming Cancer Genetics programme.\***Key****Relative** = first degree or second degree relative only, except when calculating a Manchester score\*. Female relatives through an intervening male shift up one degree of relationship\***BC** = breast cancer **MBC** = male breast cancer **OC** = ovarian cancer**Triple negative breast cancer** = breast tumour negative for oestrogen receptor (ER), progesterone receptor (PR) and HER2 Expression**CIGMA**=Clinical Impact of Genetic Mutation Analysis**Manchester Score\***

Cancer, age at diagnosis	Score
♀ <b>Breast Cancer, &lt;30</b>	<b>11</b>
♀ <b>Breast Cancer, 30-39</b>	<b>8</b>
♀ <b>Breast Cancer, 40-49</b>	<b>6</b>
♀ <b>Breast Cancer, 50-59</b>	<b>4</b>
♀ <b>Breast Cancer, &gt; 59</b>	<b>2</b>
♂ <b>Breast Cancer, &lt;60</b>	<b>13</b>
♂ <b>Breast Cancer, &gt; 59</b>	<b>10</b>
<b>Ovarian Cancer, &lt;60</b>	<b>13</b>
<b>Ovarian Cancer, &gt;59</b>	<b>10</b>
<b>Pancreatic Cancer</b>	<b>1</b>
<b>Prostate Cancer, &lt;60</b>	<b>2</b>
<b>Prostate Cancer, &gt;59</b>	<b>1</b>